Brind.

Integrated BioPharma Reports Financial Losses for Fiscal Year Ended June 30, 2026

2 reports, 2 independent Updated Sep 25
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Integrated BioPharma announced financial results from its Hillside, NJ location for the quarter and fiscal year ended June 30, 2026. For the quarter, revenues were $9.8 million, a 31.0% decrease from the previous year's $14.2 million. The company reported an operating loss of $0.9 million for the quarter. For the fiscal year, revenues reached $43.9 million, down 19.3% from the prior year's $54.4 million, resulting in a net loss of approximately $2.8 million for the fiscal year.

From finanznachrichten.de, pr-inside.com

Why it matters

Some supportBrind's analysis of the reports

The company shifted from reporting operating income in the prior fiscal year to operating losses in the current fiscal year. The net loss for the fiscal year ended June 30, 2026, was approximately $2.8 million.

From finanznachrichten.de

Who's involved

  • HillsideLocation from which the company announced its financial results.
  • Christina KayResearcher and co-leader of Integrated BioPharma.
  • BioPharmaCompany whose financial results were announced.

Keep exploring

The entities involved

  • Hillside

    township in Union County, New Jersey, United States

    Nothing else this week.

  • Christina Kay

    researcher (ORCID 0000-0002-2827-6012)

    Nothing else this week.

Coverage

Newest first; wire copies grouped